Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31667388 | 0.73 | IL4I1 (0.40) | TDP1ATMEPHX2PPARGPDE10A | |
| SCHEMBL32686754 | 0.71 | NPC1 (0.43) | NPC1MIFALDH1A1TNIKTP53 | |
| SCHEMBL32686737 | 0.71 | NPC1 (0.40) | NPC1MIFALDH1A1TNIKTSHR | |
| SCHEMBL30804530 | 0.70 | TSHR (0.55) | NPC1MIFALDH1A1POLBATM | |
| SCHEMBL31667435 | 0.69 | MIF (0.53) | NPC1MIFALDH1A1POLBTSHR | |
| SCHEMBL32686819 | 0.69 | MEN1 (0.42) | NPC1MIFALDH1A1POLBTNIK | |
| SCHEMBL32686732 | 0.68 | NPC1 (0.37) | NPC1MIFALDH1A1TDP1POLB | |
| SCHEMBL32686912 | 0.68 | TNIK (0.36) | NPC1MIFPOLBIDO1TNIK | |
| SCHEMBL14800038 | 0.67 | MIF (0.44) | NPC1MIFALDH1A1TDP1TNIK | |
| SCHEMBL18189848 | 0.67 | NPC1 (0.52) | NPC1MIFALDH1A1TNIKTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | NPC1 200/4885MIF 4403/4885ALDH1A1 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.